LFG
MLYS icon

Larson Financial Group’s Mineralys Therapeutics MLYS Stock Holding History

Larson Financial Group’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$162 Hold
6
– – ﹤0.01% 3618
2026
Q1 		$163 Sell
6
-148
-96% -$4.34K ﹤0.01% 3476
2025
Q4 		$5.59K Buy
154
+124
+413% +$4.97K ﹤0.01% 2409
2025
Q3 		$1.14K Buy
30
+24
+400% +$519 ﹤0.01% 2882
2025
Q2 		$81 Buy
+6
New +$87 ﹤0.01% 3190

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Larson Financial Group's MLYS Position: Q2 2026 in Review

Larson Financial Group held its Mineralys Therapeutics (MLYS) position steady in Q2 2026 at 6 shares worth $162. The position accounts for ﹤0.01% of the portfolio, ranked #3618.

Larson Financial Group first reported a position in MLYS in Q2 2025 and has held it in 5 quarters since. The position peaked at $5.59K in Q4 2025. 225 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Larson Financial Group held 6 shares of Mineralys Therapeutics worth $162 as of Q2 2026.
  • Larson Financial Group left its Mineralys Therapeutics share count unchanged in Q2 2026.
  • Mineralys Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #3618 holding.
  • Larson Financial Group first reported a position in Mineralys Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Larson Financial Group's Mineralys Therapeutics position peaked at $5.59K in Q4 2025.
  • 225 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.